Proscar is a brand name of finasteride, approved by the FDA in the following formulation(s):
PROSCAR (finasteride - tablet; oral)
Manufacturer: MERCK
Approval date: June 19, 1992
Strength(s): 5MG [RLD][AB]
Has a generic version of Proscar been approved?
A generic version of Proscar has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Proscar and have been approved by the FDA:
finasteride tablet; oral
Manufacturer: ACCORD HLTHCARE INC
Approval date: February 23, 2010
Strength(s): 5MG [AB]
Manufacturer: ACTAVIS TOTOWA
Approval date: March 28, 2007
Strength(s): 5MG [AB]
Manufacturer: AUROBINDO PHARMA
Approval date: October 30, 2007
Strength(s): 5MG [AB]
Manufacturer: DR REDDYS LABS LTD
Approval date: February 28, 2007
Strength(s): 5MG [AB]
Manufacturer: GEDEON RICHTER USA
Approval date: December 22, 2006
Strength(s): 5MG [AB]
Manufacturer: HETERO DRUGS LTD
Approval date: June 7, 2010
Strength(s): 5MG [AB]
Manufacturer: MYLAN
Approval date: December 18, 2006
Strength(s): 5MG [AB]
Manufacturer: SUN PHARMA GLOBAL
Approval date: August 16, 2011
Strength(s): 5MG [AB]
Manufacturer: TEVA
Approval date: December 15, 2006
Strength(s): 5MG [AB]
Manufacturer: ZYDUS PHARMS USA INC
Approval date: December 28, 2009
Strength(s): 5MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Proscar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Finasteride processes
Patent 5,886,184
Issued: March 23, 1999
Inventor(s): Dolling; Ulf H. & McCauley; James A. & Varsolona; Richard J.
Assignee(s): Merck & Co., Inc.
Disclosed is a new process for producing finasteride which involves reacting the magnesium halide salt of 17.beta.-carboalkoxy-4-aza-5.alpha.-androst-1-en-3-one with t-butylamino magnesium halide, present in at least a 2:1 molar ratio to the ester, formed from t-butyl amine and an aliphatic/aryl magnesium halide at ambient temperature in an inert organic solvent under an inert atmosphere followed by heating and recovering the product finasteride. Also disclosed are two polymorphic crystalline Forms I and II of finasteride, and methods of their production.Patent expiration dates:
- November 19, 2012✓
- November 19, 2012
Prevention of precipitated acute urinary retention
Patent 5,942,519
Issued: August 24, 1999
Inventor(s): Waldstreicher; Joanne
Assignee(s): Merck & Co., Inc.
This invention is concerned with the prevention of precipitated acute urinary retention in a subject male susceptible thereto by the administration of an inhibitor of 5.alpha.-reductase to the subject. The present invention also provides for a method of reducing the risk of precipitated acute urinary retention by the administration of a 5.alpha.-reductase inhibitor to the subject at risk therefor.Patent expiration dates:
- October 23, 2018✓
- October 23, 2018
See also...
- Proscar Consumer Information (Drugs.com)
- Proscar Consumer Information (Wolters Kluwer)
- Proscar Consumer Information (Cerner Multum)
- Proscar Advanced Consumer Information (Micromedex)
- Finasteride Consumer Information (Wolters Kluwer)
- Finasteride Consumer Information (Cerner Multum)
- Finasteride Advanced Consumer Information (Micromedex)
- Finasteride AHFS DI Monographs (ASHP)
No comments:
Post a Comment